AMGN · News · 20260805N
Product Pipeline Progress
AMGEN INC · 2026-08-05 · Importance 28 · Surprise 42 · In source text
Amgen is continuing late-stage development of MariTide, its investigational obesity treatment, including the Phase 3 MARITIME-1-EXTENSION study evaluating long-term weight-loss maintenance and tolerability. The company is also advancing Phase 3 programs for key growth drivers and expects future catalysts from MariTide and olpasiran. Amgen discontinued early development of AMG 513, an obesity candidate in a Phase 1 study, while maintaining its broader focus on the obesity market. Pipeline expansion is being supported by increased investment in late-stage clinical programs.
Key facts
- Amgen reported it expects key pipeline catalysts including MariTide and olpasiran Phase 3 readouts in 2027–2028 (seekingalpha commentary). source
- Amgen announced in TipRanks that it extended its Phase 3 MARITIME-1-EXTENSION study for maridebart cafraglutide (AMG 133 or MariTide) to assess long-term efficacy and safety. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Amgen reported it expects key pipeline catalysts including MariTide and olpasiran Phase 3 readouts in 2027–2028 (seekingalpha commentary). |